{"title":"培菲康联合美沙拉嗪对溃疡性结肠炎患者临床疗效观察","authors":"于京芳, 李帅, 谭杰, 江学良","doi":"10.63887/cn.2025.1.7.18","DOIUrl":"https://doi.org/10.63887/cn.2025.1.7.18","url":null,"abstract":"验证培菲康联合美沙拉嗪治疗溃疡性结肠炎的临床有效性和安全性,并为粪便钙卫蛋白的临床应用提供临床依据。方法:本研究将符合纳排标准的60例患者随机分为对照组(美沙拉嗪4g/日)、治疗组(美沙拉嗪4g/日+双歧杆菌三联活菌(培菲康)0.84g/日),疗程8周。运用SPSS27.0统计学软件分析治疗前后两组患者粪便钙卫蛋白含量、实验室指标等变化。结果:1.培菲康联合美沙拉嗪治疗可以降低溃疡性结肠炎患者粪便钙卫蛋白含量,差异有统计学意义(P<0.05)。2.培菲康联合美沙拉嗪治疗可以降低C反应蛋白含量减轻炎症反应,但差异无统计学意义(P>0.05)。3.培菲康联合美沙拉嗪治疗可以提高白蛋白含量改善患者营养状况,治疗组差异有统计学意义(组内P<0.05)。结论:培菲康联合美沙拉嗪治疗对溃疡性结肠炎患者临床安全有效,可降低粪便钙卫蛋白含量,减轻炎症反应,改善患者营养状况。","PeriodicalId":61242,"journal":{"name":"中华临床医药与护理","volume":"1 7","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sci-open.net/index.php/CN/article/download/5080/6636","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147890378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0